AstraZeneca’s weak performance continued in Q3, reflecting a higher than expected decline in Crestor and Symbicort sales, although the revenue drop was capped at 4% (vs 10% in Q2) to $5.7bn. This reflected a decline in product sales of 14% (vs 5% in Q2) to $5bn, partly offset by high externalisation revenue ($674m vs $134m in Q2; $520m ytd was received from the commercial rights to Aspen’s anaesthetics portfolio). All growth numbers at CER unless specific otherwise. Nine months re
24 Jan 2017
Generic threat endangers, but Oncology looks promising
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Generic threat endangers, but Oncology looks promising
AstraZeneca PLC (AZN:LON) | 10,715 -3000.2 (-0.3%) | Mkt Cap: 166,105m
- Published:
24 Jan 2017 -
Author:
Kamla Singh -
Pages:
4
AstraZeneca’s weak performance continued in Q3, reflecting a higher than expected decline in Crestor and Symbicort sales, although the revenue drop was capped at 4% (vs 10% in Q2) to $5.7bn. This reflected a decline in product sales of 14% (vs 5% in Q2) to $5bn, partly offset by high externalisation revenue ($674m vs $134m in Q2; $520m ytd was received from the commercial rights to Aspen’s anaesthetics portfolio). All growth numbers at CER unless specific otherwise. Nine months re